Savara (NASDAQ:SVRA) Releases Earnings Results, Beats Estimates By $0.01 EPS

Savara (NASDAQ:SVRA) released its earnings results on Monday. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.01, reports.

Savara Stock Up 3.8%

Shares of Savara stock traded up $0.18 during trading hours on Wednesday, reaching $5.11. The company’s stock had a trading volume of 4,315,732 shares, compared to its average volume of 1,768,910. Savara has a one year low of $4.03 and a one year high of $7.01. The company has a market capitalization of $1.05 billion, a P/E ratio of -8.80 and a beta of 0.32. The stock’s fifty day simple moving average is $4.97 and its two-hundred day simple moving average is $5.35. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.13 and a current ratio of 10.13.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. JPMorgan Chase & Co. began coverage on shares of Savara in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research note on Thursday, October 15th. Royal Bank Of Canada set a $10.00 target price on Savara in a research report on Wednesday, October 7th. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a research note on Wednesday, October 7th. Finally, Wall Street Zen downgraded Savara from a “hold” rating to a “sell” rating in a research note on Sunday, October 4th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $10.25.

Savara Company Profile

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.